Please wait a minute...
文章检索
预防医学  2017, Vol. 29 Issue (12): 1199-1202    DOI: 10.19485/j.cnki.issn1007-0931.2017.12.003
  论著 本期目录 | 过刊浏览 | 高级检索 |
浙江省实施脊髓灰质炎疫苗免疫新策略的卫生经济学评价
唐学雯,周洋,邓璇,严睿,谢淑云,何寒青
浙江省疾病预防控制中心,浙江 杭州 310051
Economic evaluation on new strategy for preventing poliomyelitis in Zhejiang Province
TANG Xue-wen,ZHOU Yang,DENG Xuan,YAN Rui,XIE Shu-yun,HE Han-qing
Zhejiang Provincial Center for Disease Control and Prevention,Hangzhou,Zhejiang,310051,China
全文: PDF(501 KB)  
输出: BibTeX | EndNote (RIS)      
摘要 目的 评价浙江省2016年实施脊髓灰质炎(脊灰)疫苗免疫新策略后的成本效益。方法 以浙江省2016年人口为基数,以不接种策略为参照,采用成本效果比(CER)、效益成本比(BCR)和净收益(NB)等指标比较脊灰疫苗免疫新策略和原策略的成本效益,并通过调整疾病成本、疫苗价格、贴现率和接种成本进行敏感性分析。结果 脊灰疫苗免疫新策略的CER发病为1:5.27(例/万元),CER死亡为1:181.37(例/万元),BCR为12.26,NB为79 666.22万元;原策略的CER发病为1:3.29(例/万元),CER死亡为1:113.39(例/万元),BCR为19.58,NB为82 317.53万元。敏感性分析结果显示,原策略和新策略的卫生经济学评价效果一致,BCR变化幅度≤25%;疾病负担变化引起的BCR变化最大,疾病负担(80%~120%)调整后,原策略BCR变化在15.66~23.50之间,新策略BCR变化在9.81~14.71之间。结论 实施脊灰疫苗免疫新策略是现阶段全球消灭脊灰的客观要求,新策略的成本效益略低于原策略,但仍具有较好的卫生经济学意义。
服务
把本文推荐给朋友
加入引用管理器
E-mail Alert
RSS
作者相关文章
唐学雯
周洋
邓璇
严睿
谢淑云
何寒青
关键词 脊髓灰质炎免疫策略卫生经济学评价    
AbstractObjective To evaluate the economic effect of new strategy for preventing poliomyelitis in Zhejiang Province. Methods Based on the population of Zhejiang Province in 2016,cost-effectiveness ratio(CER),benefit-cost ratio(BCR),and net benefit(NB)were applied to calculate the health economic difference for the new strategy and the original strategy as compared to no vaccination strategy. Univariate sensitivity analysis was used to assess the robustness of results with main parameters; including burdens of poliomyelitis,cost of vaccines,and the vaccination program itself,and the discount rate. Results CERdisease,CERdeath,BCR and NB for the new strategy were 1:52700 RMB Yuan per case,1:1813700 RMB Yuan per case,12.26 and 796.6622 million and CERdisease,CERdeath,BCR and NB for the original strategy were 1:32900 RMB Yuan per case,1:1133900 RMB Yuan per case,19.58 and 823.1753 million,respectively. The results of the univariate sensitivity analysis with main parameters were robust. Conclusion The new strategy for preventing poliomyelitis is necessary for this period of the global polio eradication. Though the new strategy appears not as good as the original strategy on economic evaluation,its health economic benefit is significant.
Key wordsPoliomyelitis    Vaccination program    Health economic
         
中图分类号:  R186  
基金资助:浙江省医药卫生一般研究计划(2016KYB061);浙江省预防医学会软课题(2016YF02)
通信作者: 何寒青,E-mail:hanqinghe@cdc.zj.cn   
作者简介: 唐学雯,本科,主管医师,主要从事免疫针对疾病监测工作
引用本文:   
唐学雯,周洋,邓璇,严睿,谢淑云,何寒青. 浙江省实施脊髓灰质炎疫苗免疫新策略的卫生经济学评价[J]. 预防医学, 2017, 29(12): 1199-1202.
TANG Xue-wen,ZHOU Yang,DENG Xuan,YAN Rui,XIE Shu-yun,HE Han-qing. Economic evaluation on new strategy for preventing poliomyelitis in Zhejiang Province. Preventive Medicine, 2017, 29(12): 1199-1202.
链接本文:  
http://www.zjyfyxzz.com/CN/10.19485/j.cnki.issn1007-0931.2017.12.003      或      http://www.zjyfyxzz.com/CN/Y2017/V29/I12/1199
[1] WHO.Polio Vaccines:WHO Position Paper,January 2014[Z]. WER,2014,89(9):73-92.
[2] Global Poliomyelitis Eradication Initiative.Poliomyelitis eradication and endgame strategic plan,2013—2018[EB/OL]. http:// www.poliomyelitis eradication.org/Portals/0/Document/Resour- Ces/ Straregy Work/EndgameStratPlan-20130409_ENG.pdf.
[3] DUINTJER,TEBBENS R J,THOMPSON K M.The potential benefits of a new poliovirus vaccine for long-term poliovirus risk management[J]. Future Microbiol,2016(11):1549-1561.
[4] WHO. 全球消灭脊髓灰质炎前的脊髓灰质炎疫苗及其免疫接种:WHO立场文件[Z]. 2010.
[5] WHO.Polio Vaccines:WHO position paper-March,2016[Z]. WER,2016,91( 12 ):145-168.
[6] ARITA M. Poliovirus Studies during the Endgame of the Polio Eradication Program[J]. Jpn J Infect Dis,2017,70(1):1-6.
[7] KHAN M T,ZAHEER S,SHAFIQUE K. Maternal education,empowerment,economic status and child polio vaccination uptake in Pakistan:a population based cross sectional study[J]. BMJ Open,2017,7(3):e013853.
[8] LI R C,LI C G,WANG H B,et al. Immunogenicity of two different sequential schedules of inactivated polio vaccine followed by oral polio vaccine versus oral polio vaccine alone in healthy infants in China[J]. J Pediatric Infect Dis Soc,2016,5(3):287-296.
[9] 何寒青,陈恩富,李倩,等. 浙江省1978—2007年计划免疫卫生经济学评价[J]. 中国农村卫生事业管理,2010,30(10):835-837.
[10]World Health Organization.WHO guide for standardization of economic evaluations of immunization program[M]. Geneva:WHO Document Production Services,2008:56-57.
[11]ZHOU F,ORTEGA-SANCHEZ I R,GURIS D,et al. An economic analysis of the universal varicella vaccination program in the United States[J]. J Infect Dis,2008,197(Suppl 2):S156-S164.
[12]何寒青,张兵,严睿,等. 不同免疫程序接种2剂麻疹-流行性腮腺炎-风疹联合减毒活疫苗的卫生经济学评价[J]. 中华流行病学杂志,2016,37(8):1121-1126.
[13]孙烨祥,林鸿波,李珊燕. 首剂IPV纳入免疫规划前儿童脊髓灰质炎疫苗接种情况分析[J]. 预防医学,2017,29(4):368-371.
[14]刘白羽,刘勇,王少华. 山东省脊髓灰质炎计划免疫的社会效果与经济效益[J]. 中国公共卫生管理杂志,1991(S1):287.
[1] 唐学雯, 龚黎明, 周洋, 严睿, 邓璇, 朱瑶, 何寒青. 浙江省1例AFP病例检出脊髓灰质炎疫苗高变异株病毒的流行病学调查[J]. 预防医学, 2023, 35(1): 65-67.
[2] 龚震宇, 龚训良. 全球消除脊髓灰质炎进展[J]. 预防医学, 2022, 34(8): 861-862.
[3] 陈恩富. 疫苗时代新型冠状病毒肺炎疫情防控策略[J]. 预防医学, 2021, 33(3): 221-225.
[4] 王富良,刘仕俊,孙向珏,杜渐. 一起脊髓灰质炎减毒活疫苗接种偶合死亡案例分析[J]. 预防医学, 2018, 30(9): 943-945.
[5] 孙烨祥,林鸿波,李珊燕. 首剂IPV纳入免疫规划前儿童脊髓灰质炎疫苗接种情况分析[J]. 预防医学, 2017, 29(4): 368-371.
[6] 李倩, 胡昱, 张兵, 陈雅萍. 7岁以下儿童接种1剂次或2剂次Salk-IPV免疫效果的Meta分析[J]. 预防医学, 2016, 28(9): 874-878,895.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed